The company believes its product, called Constellation, will differentiate itself from current commercial offerings in terms of throughput and multiplexing capability.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
The firm recently released two droplet digital PCR-based assays that can characterize edits generated by CRISPR-Cas9 or other genome editing tools.
Researchers combined a microfluidic technology called the CTC-iChip with digital PCR to potentially improve cancer detection in hepatocellular carcinoma patients.
University of Cambridge researchers found that the portion of tumor DNA in patients' blood could predict treatment response and time to disease progression.
Esoterix sued Myriad in September, claiming that its myRisk Hereditary Cancer panel and services directly infringe four patents it has exclusively licensed.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
A University of Michigan Health System team showed that heat fragmentation leads to increased detection of a G-to-A mutation of the KRAS gene in vendor-purchased DNA.
Two Boston-based researchers shared methods for detecting circulating nucleic acid biomarkers for potential use in cancer diagnosis and monitoring.
Bio-Rad reported $570.6 million in revenues in Q4, a 5 percent drop year over year but a 3 percent increase on a currency-neutral basis.
New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.
Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.
La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.
In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.